ArticleMolecular and cellular biology2004
FANCG is phosphorylated at serines 383 and 387 during mitosis.
Article in Molecular and cellular biology, 2004. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 38 citations in OpenAlex.
- Review
- Cellular response to DNA interstrand crosslinks: the Fanconi anemia pathway.Cellular and molecular life sciences : CMLS · 2016Review
- Abundance of the Fanconi anaemia core complex is regulated by the RuvBL1 and RuvBL2 AAA+ ATPases.Nucleic acids research · 2014Article
- Fanconi anemia and the cell cycle: new perspectives on aneuploidy.F1000prime reports · 2014Review
- Fanconi anemia: a signal transduction and DNA repair pathway.The Yale journal of biology and medicine · 2013Review
- Fanconi anemia signaling network regulates the spindle assembly checkpoint.The Journal of clinical investigation · 2013Article
- Article
- Ubiquitylation and the Fanconi anemia pathway.FEBS letters · 2011Review
- The Fanconi anemia pathway and ICL repair: implications for cancer therapy.Critical reviews in biochemistry and molecular biology · 2010Review
- Significance of the Fanconi anemia FANCD2 protein in sporadic and metastatic human breast cancer.The American journal of pathology · 2010Article
- Fanconi anemia complementation group FANCD2 protein serine 331 phosphorylation is important for fanconi anemia pathway function and BRCA2 interaction.Cancer research · 2009Article
- The Fanconi anemia protein interaction network: casting a wide net.Mutation research · 2009Review
- Fanconi anemia.Hematology/oncology clinics of North America · 2009Review
- ATR-dependent phosphorylation of FANCA on serine 1449 after DNA damage is important for FA pathway function.Blood · 2009Article
- FANCG promotes formation of a newly identified protein complex containing BRCA2, FANCD2 and XRCC3.Oncogene · 2008Article
- The Fanconi anemia core complex is required for efficient point mutagenesis and Rev1 foci assembly.DNA repair · 2008Article
- UBE2T, the Fanconi anemia core complex, and FANCD2 are recruited independently to chromatin: a basis for the regulation of FANCD2 monoubiquitination.Molecular and cellular biology · 2007Article
- Phosphorylation of FANCD2 on two novel sites is required for mitomycin C resistance.Molecular and cellular biology · 2006Article
- Molecular pathogenesis of Fanconi anemia.International journal of hematology · 2005Review
- Phosphorylation states of cell cycle and DNA repair proteins can be altered by the nsSNPs.BMC cancer · 2005Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 4 institutions in 2 countries.
Funding
Abstract
Fanconi anemia (FA) is an autosomal recessive disease marked by congenital defects, bone marrow failure, and high incidence of leukemia and solid tumors. Eight genes have been cloned, with the accompanying protein products participating in at least two complexes, which appear to be functionally dependent upon one another. Previous studies have described chromatin localization of the FA core complex, except at mitosis, which is associated with phosphorylation of the FANCG protein (F. Qiao, A. Moss, and G. M. Kupfer, J. Biol. Chem. 276:23391-23396, 2001). The phosphorylation of FANCG at serine 7 by using mass spectrometry was previously mapped. The purpose of this study was to map the phosphorylation sites of FANCG at mitosis and to assess their functional importance. Reasoning that a potential kinase might be cdc2, which was previously reported to bind to FANCC, we showed that cdc2 chiefly phosphorylated a 14-kDa fragment of the C-terminal half of FANCG. Mass spectrometry analysis demonstrated that this fragment contains amino acids 374 to 504. Kinase motif analysis demonstrated that three amino acids in this fragment were leading candidates for phosphorylation. By using PCR-directed in vitro mutagenesis we mutated S383, S387, and T487 to alanine. Mutation of S383 and S387 abolished the phosphorylation of FANCG at mitosis. These results were confirmed by use of phosphospecific antibodies directed against phosphoserine 383 and phosphoserine 387. Furthermore, the ability to correct FA-G mutant cells of human or hamster (where S383 and S387 are conserved) origin was also impaired by these mutations, demonstrating the functional importance of these amino acids. S387A mutant abolished FANCG fusion protein phosphorylation by cdc2. The FA pathway, of which FANCG is a part, is highly regulated by a series of phosphorylation steps that are important to its overall function.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.